These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Comparison of hyperemic efficacy between central and peripheral venous adenosine infusion for fractional flow reserve measurement. Seo MK; Koo BK; Kim JH; Shin DH; Yang HM; Park KW; Lee HY; Kang HJ; Kim HS; Oh BH; Park YB Circ Cardiovasc Interv; 2012 Jun; 5(3):401-5. PubMed ID: 22647519 [TBL] [Abstract][Full Text] [Related]
25. Fractional Flow Reserve in the Transradial Era: Will Hand Vein Adenosine Infusion Suffice?: A Comparative Study of the Extent, Rapidity, and Stability of Hyperemia From Hand and Femoral Venous Routes of Adenosine Administration. Scott P; Sirker A; Dworakowski R; Paul G; Candilio L; Jahagirdar N; Melikian N; Byrne J JACC Cardiovasc Interv; 2015 Apr; 8(4):527-35. PubMed ID: 25819188 [TBL] [Abstract][Full Text] [Related]
26. The effect of obesity on regadenoson-induced myocardial hyperemia: a quantitative magnetic resonance imaging study. DiBella EV; Fluckiger JU; Chen L; Kim TH; Pack NA; Matthews B; Adluru G; Priester T; Kuppahally S; Jiji R; McGann C; Litwin SE Int J Cardiovasc Imaging; 2012 Aug; 28(6):1435-44. PubMed ID: 21968545 [TBL] [Abstract][Full Text] [Related]
27. Comparison of the intracoronary continuous infusion method using a microcatheter and the intravenous continuous adenosine infusion method for inducing maximal hyperemia for fractional flow reserve measurement. Yoon MH; Tahk SJ; Yang HM; Park JS; Zheng M; Lim HS; Choi BJ; Choi SY; Choi UJ; Hwang JW; Kang SJ; Hwang GS; Shin JH Am Heart J; 2009 Jun; 157(6):1050-6. PubMed ID: 19464416 [TBL] [Abstract][Full Text] [Related]
28. Comparison of the novel vasodilator uridine triphosphate and adenosine for the measurement of fractional flow reserve. Sivertsen J; Jensen J; Galatius S; Raunsø J; Rosenmeier J J Invasive Cardiol; 2014 Oct; 26(10):512-8. PubMed ID: 25274861 [TBL] [Abstract][Full Text] [Related]
29. Myocardial perfusion imaging laboratory efficiency with the use of regadenoson compared to adenosine and dipyridamole. Friedman M; Spalding J; Kothari S; Wu Y; Gatt E; Boulanger L J Med Econ; 2013; 16(4):449-60. PubMed ID: 23363331 [TBL] [Abstract][Full Text] [Related]
30. Impact of additional intracoronary nicorandil administration during fractional flow reserve measurement with intravenous adenosine 5'-triphosphate infusion. Takami H; Sonoda S; Muraoka Y; Sanuki Y; Kashiyama K; Fukuda S; Oginosawa Y; Tsuda Y; Araki M; Otsuji Y J Cardiol; 2017 Jan; 69(1):119-124. PubMed ID: 26947100 [TBL] [Abstract][Full Text] [Related]
31. Comparison of intravenous adenosine to intracoronary papaverine for calculation of pressure-derived fractional flow reserve. van der Voort PH; van Hagen E; Hendrix G; van Gelder B; Bech JW; Pijls NH Cathet Cardiovasc Diagn; 1996 Oct; 39(2):120-5. PubMed ID: 8922309 [TBL] [Abstract][Full Text] [Related]
32. [A novel way to induce coronary hyperaemia]. Tkaczewski K; Dziuk M; Kocki J; Pińkowski R Postepy Hig Med Dosw (Online); 2013 Sep; 67():933-7. PubMed ID: 24088536 [TBL] [Abstract][Full Text] [Related]
33. The role of the A2a receptor agonist, regadenoson, in modulating hepatic artery flow in the porcine small-for-size liver graft. Zhu X; Shiba H; Fung JJ; Wang LF; Arakawa Y; Irefin S; Demetris AJ; Kelly DM J Surg Res; 2012 May; 174(1):e37-45. PubMed ID: 22225980 [TBL] [Abstract][Full Text] [Related]
34. Effect of caffeine on intravenous adenosine-induced hyperemia in fractional flow reserve measurement. Matsumoto H; Nakatsuma K; Shimada T; Ushimaru S; Mikuri M; Yamazaki T; Matsuda T J Invasive Cardiol; 2014 Nov; 26(11):580-5. PubMed ID: 25363999 [TBL] [Abstract][Full Text] [Related]
35. Caffeine attenuates the duration of coronary vasodilation and changes in hemodynamics induced by regadenoson (CVT-3146), a novel adenosine A2A receptor agonist. Zhao G; Messina E; Xu X; Ochoa M; Sun HL; Leung K; Shryock J; Belardinelli L; Hintze TH J Cardiovasc Pharmacol; 2007 Jun; 49(6):369-75. PubMed ID: 17577101 [TBL] [Abstract][Full Text] [Related]
36. Regadenoson for FFR: time to say good-bye to adenosine? Hakeem A; Uretsky B Catheter Cardiovasc Interv; 2014 Feb; 83(3):375-6. PubMed ID: 24497454 [No Abstract] [Full Text] [Related]
37. Comparison of effectiveness of high-dose intracoronary adenosine versus intravenous administration on the assessment of fractional flow reserve in patients with coronary heart disease. López-Palop R; Carrillo P; Frutos A; Cordero A; Agudo P; Mashlab S; Bertomeu-Martínez V Am J Cardiol; 2013 May; 111(9):1277-83. PubMed ID: 23415635 [TBL] [Abstract][Full Text] [Related]
39. Common genetic polymorphisms of adenosine A2A receptor do not influence response to regadenoson. Berlacher M; Mastouri R; Philips S; Skaar TC; Kreutz RP Pharmacogenomics; 2017 Apr; 18(6):523-529. PubMed ID: 28358597 [TBL] [Abstract][Full Text] [Related]
40. Importance of guiding catheter disengagement during measurement of fractional flow reserve in patients with an isolated proximal left anterior descending artery stenosis. Aminian A; Dolatabadi D; Lefebvre P; Khalil G; Zimmerman R; Michalakis G; Lalmand J Catheter Cardiovasc Interv; 2015 Mar; 85(4):595-601. PubMed ID: 24909128 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]